EP4049680 - NOVEL SUBSTITUTED CONDENSED RING COMPOUND [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 29.07.2022 Database last updated on 19.10.2024 | |
Former | The international publication has been made Status updated on 03.05.2021 | Most recent event Tooltip | 05.07.2024 | Amendment by applicant | Applicant(s) | For all designated states Sumitomo Pharma Co., Ltd. 6-8, Doshomachi 2-chome Chuo-ku Osaka-shi Osaka 541-0045 / JP | [2022/35] | Inventor(s) | 01 /
KOIKE, Sachiko c/o Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku Osaka-shi, Osaka 554-0022 / JP | 02 /
IKUMA, Yohei c/o Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku Osaka-shi, Osaka 554-0022 / JP | 03 /
FUKAYA, Takayuki c/o Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku Osaka-shi, Osaka 554-0022 / JP | 04 /
UESUGI, Shunichiro c/o Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku Osaka-shi, Osaka 554-0022 / JP | [2022/35] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstraße 3 81675 München / DE | [2022/35] | Application number, filing date | 20880018.5 | 23.10.2020 | [2022/35] | WO2020JP39897 | Priority number, date | JP20190194753 | 25.10.2019 Original published format: JP 2019194753 | [2022/35] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021079984 | Date: | 29.04.2021 | Language: | JA | [2021/17] | Type: | A1 Application with search report | No.: | EP4049680 | Date: | 31.08.2022 | Language: | EN | [2022/35] | Search report(s) | International search report - published on: | JP | 29.04.2021 | (Supplementary) European search report - dispatched on: | EP | 13.12.2023 | Classification | IPC: | A61K45/00, A61P1/02, A61P1/16, A61P7/00, A61P9/00, A61P11/00, A61P11/02, A61P11/04, A61P13/02, A61P15/00, A61P19/02, A61P27/02, A61P27/16, A61P29/00, A61P31/04, A61P31/10, A61P31/12, A61P37/08, A61P43/00, C07F5/02, A61P17/00 | [2022/35] | CPC: |
A61P1/02 (EP);
C07F5/025 (EP,KR,US);
A61K31/352 (EP);
A61K31/397 (EP);
A61K31/69 (KR);
A61K45/06 (EP);
A61P1/16 (EP);
A61P11/00 (EP);
A61P11/02 (EP);
A61P11/04 (EP);
A61P13/02 (EP);
A61P15/00 (EP);
A61P17/00 (EP);
A61P17/02 (EP);
A61P19/02 (EP);
A61P27/02 (EP);
A61P27/16 (EP);
A61P29/00 (EP);
A61P31/04 (EP,KR);
A61P31/10 (EP);
A61P31/12 (EP);
A61P37/08 (EP);
A61P43/00 (EP);
A61P7/00 (EP);
| C-Set: |
A61K31/352, A61K2300/00 (EP);
A61K31/397, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/35] | Title | German: | NEUARTIGE SUBSTITUIERTE KONDENSIERTE RINGVERBINDUNG | [2022/35] | English: | NOVEL SUBSTITUTED CONDENSED RING COMPOUND | [2022/35] | French: | NOUVEAU COMPOSÉ CYCLIQUE CONDENSÉ SUBSTITUÉ | [2022/35] | Entry into regional phase | 23.05.2022 | Translation filed | 23.05.2022 | National basic fee paid | 23.05.2022 | Search fee paid | 23.05.2022 | Designation fee(s) paid | 23.05.2022 | Examination fee paid | Examination procedure | 23.05.2022 | Examination requested [2022/35] | 04.07.2024 | Amendment by applicant (claims and/or description) | 04.07.2024 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 24.10.2022 | Renewal fee patent year 03 | 23.10.2023 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2018005662 (REMPEX PHARMACEUTICALS INC [US]) [Y] 1-26* boronic acid tricyclic heterocycles and their use in pharmaceutical compositions (see claims 77-81) and for treatment of bacterial infections (see claims 84-88) through beta-lactamase inhibition (see claims 80 and 87). *; | [YP]WO2019208797 (SUMITOMO DAINIPPON PHARMA CO LTD [JP], et al) [YP] 1-26 * compounds of table 3, pages 561-564; use of compounds as beta-lactamase inhibitors (see claim 72), in pharmaceutical compositions (see claims 84-85) and for treatment of bacterial infections (see claims 86-89) * | International search | [A]JP2014524446 (GLAXOSMITHKLINE LLC) [A] 1-143* claims 1-13 *; | [A]JP2014527529 (GLAXO GROUP LIMITED) [A] 1-143 * claims 1-22 *; | [A]WO2016149393 (REMPEX PHARMACEUTICALS INC [US]) [A] 1-143 * claims 1-154 *; | [A]JP2017517508 (REMPEX PHARMACEUTICALS, INC.) [A] 1-143 * claims 1-118 *; | [A]WO2019009369 (SUMITOMO DAINIPPON PHARMA CO LTD [JP], et al) [A] 1-143 * claims 1-121 * | by applicant | - BUYNAK. JD, Expert Opinion on Therapeutic Patents, (20130000), vol. 23, no. 11, pages 1469 - 1481 |